Impact of invasive nodal staging on regional and distant recurrence rates after SBRT for inoperable stage I NSCLC
Author:
Funder
Alvin J. Siteman Cancer Center
National Cancer Institute
Publisher
Elsevier BV
Subject
Radiology, Nuclear Medicine and imaging,Oncology,Hematology
Reference34 articles.
1. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer;Timmerman;JAMA Oncol,2018
2. Stereotactic body radiation therapy versus conventional radiation therapy in patients with early stage non-small cell lung cancer: an updated retrospective study on local failure and survival rates;Jeppesen;Acta Oncol Stockh Swed,2013
3. SPACE – A randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC;Nyman;Radiother Oncol,2016
4. Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer;Haque;Radiother,2018
5. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC);von Reibnitz;Acta Oncol,2018
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer – Results from a Single Institution Study;Clinical Lung Cancer;2024-06
2. What is new in mediastinal staging?;Current Opinion in Pulmonary Medicine;2023-10-26
3. Treatment patterns and results of salvage treatment for regional recurrences after stereotactic ablative radiotherapy for primary non‐small cell lung cancer;Asia-Pacific Journal of Clinical Oncology;2023-07-05
4. Lung cancer staging, the established role of bronchoscopy;Current Opinion in Pulmonary Medicine;2021-11-01
5. Nodal recurrences after stereotactic body radiotherapy for early stage non–small-cell lung cancer;Current Problems in Cancer;2021-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3